Virtual Pharmaceutical Company Business Model
PharmaEngine adopts the "Virtual Pharmaceutical Company Business Model" and focuses on oncology new drug development. In addition to evaluating potential candidates based on pre-clinical data to jointly develop or licensing in new drug projects, we also aggressively expanded our in-house R&D capabilities, through AI/CADD computing, to screen the best compound for pre-clinical and early clinical trial stages to find potential candidates to enhance drug value. At the later stages of clinical trials, we plan to authorize global pharmaceutical companies for selling and marketing.
PharmaEngine adopts the "Virtual Pharmaceutical Company Business Model" and focuses on oncology new drug development. In addition to evaluating potential candidates based on pre-clinical data to jointly develop or licensing in new drug projects, we also aggressively expanded our in-house R&D capabilities, through AI/CADD computing, to screen the best compound for pre-clinical and early clinical trial stages to find potential candidates to enhance drug value. At the later stages of clinical trials, we plan to authorize global pharmaceutical companies for selling and marketing.
Company Development Strategy
-
StrategyVirtual Pharmaceutical Company Business Model characteristics:- Light asset: No manufacturing facilities or storage assets.
- Lower new drug development risks: In-license international partners for cooperation.
- Accelerate product R&D and marketing: Cooperate closely with strategic partners on marketing and sales.
-
Core CompetencePharmaEngine has a team of advisors consists of international heavy-weight cancer specialists to help us make the most accruate decision in various stages and to conduct the best risk management and control.
As a Virtual Pharmaceutical Company, our capabilities stretch from compound screening to sales and marketing while cooperating with different international partners (CDMO/CRO) at various stages of development. The synergy with our partners help us accelerate efficiency and shorten R&D time.
.png)